BryanTM, EnglezouA, Dalla-PozzaL, et al.Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med, 1997; 3(11):1271-1274.
2.
ChakravartiD, DePinhoRA. Telomere dysfunction as an initiator of inflammation: Clues to an age-old mystery. J Inflamm Bowel Dis Disord, 2021; 6(2).
3.
ChenYY, DaggR, ZhangY, et al.The C-circle biomarker is secreted by alternative-lengthening-of-telomeres positive cancer cells inside exosomes and provides a blood- based diagnostic for ALT activity. Cancers (Basel), 2021; 13(21):5369.
4.
FlynnRL, CoxKE, JeitanyM, et al.Alternative lengthening of telomeres renders cancer cells hyper sensitive to ATR inhibitors. Science, 2015; 347(6219):273-277.
5.
HeaphyCM, SubhawongAP, HongS-M, et al.Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol, 2011; 179(4):1608-1615.
6.
HensonJD, CaoY, HuschtschaLI, et al.DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol, 2009; 27(12):1181-1185.
7.
HuJ, et al.Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell, 2012; 148(4):651-663.
8.
IdilliAI, Segura-BayonaS, LippertTP, et al.A C-circle assay for detection of alternative lengthening of telomere activity in FFPE tissue. STAR Protoc, 2021; 2(2):100569.
9.
KimNW, PiatyszekMA, ProwseKR, et al.Specific association of human telomerase activity with immortal cells and cancer. Science, 1994; 266(5193):2011-2015.
10.
LuR, PickettHA. Telomeric replication stress: The beginning and the end for alternative lengthening of telomeres cancers. Open Biol, 2022; 12(3):220011.
11.
LuR, O'RourkeJJ, SobinoffAP, et al.The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT). Nat Commun, 2019; 10(1):2252.
12.
MacKenzieDJr., WattersAK, ToJT, et al.ALT positivity in human cancers: Prevalence and clinical insights. Cancers (Basel), 2021; 13(10):2384.
NguyenK, WongJMY. Telomerase biogenesis and activities from the perspective of its direct interacting partners. Cancers (Basel), 2020; 12(6):1679.
15.
PanX, AhmedN, KongJ, et al.Breaking the end: Target the replication stress response at the ALT telomeres for cancer therapy. Mol Cell Oncol, 2017; 4(6):e1360978.
16.
PanX, DrosopoulosWC, SethiL, et al.FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres. Proc Natl Acad Sci U S A, 2017; 114(29):E5940-E5949.
17.
PandayA, et al.FANCM regulates repair pathway choice at stalled replication forks. Mol Cell, 2021; 81(11):2428-2444.e6.
18.
ShayJW, BacchettiS. A survey of telomerase activity in human cancer. Eur J Cancer, 1997; 33(5):787-791.
19.
ShayJW, WrightWE. Telomeres and telomerase: Three decades of progress. Nat Rev Genet, 2019; 20(5):299-309.
20.
SilvaB, PentzR, FigueiraAM, et al.FANCM limits ALT activity by restricting telomeric replication stress induced by deregulated BLM and R-loops. Nat Commun, 2019; 10(1):2253.
21.
SobinoffAP, PickettHA. Mechanisms that drive telomere maintenance and recombination in human cancers. Curr Opin Genet Dev, 2020; 60:25-30.
22.
WangH, LiS, ZhangH, et al.BLM prevents instability of structure-forming DNA sequences at common fragile sites. PLoS Genet, 2018; 14(11):e1007816.
23.
WhitbyMC.The FANCM family of DNA helicases/translocases. DNA Repair (Amst), 2010; 9(3):224-236.
24.
WuRA, UptonHE, VoganJM, et al.Telomerase mechanism of telomere synthesis. Annu Rev Biochem, 2017; 86:439-460.
25.
XuY, GoldkornA.Telomere and telomerase therapeutics in cancer. Genes (Basel), 2016; 7(6).
26.
XueX, SungP, ZhaoX. Functions and regulation of the multitasking FANCM family of DNA motor proteins. Genes Dev, 2015; 29(17):1777-1788.
27.
ZhangJM, ZouL. Alternative lengthening of telomeres: From molecular mechanisms to therapeutic outlooks. Cell Biosci, 2020; 10:30.
